Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Answering key follow-up questions after the FDA approved TAVR in asymptomatic patients
The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward.
AI predicts LBBB risk in TAVR patients prior to treatment
The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.
A super alternative: BATMAN helps cardiologists limit complications during TMVR
The BATMAN technique is a safe, effective way to prevent LVOT obstruction during high-risk transcatheter mitral valve replacement, according to new data presented at SCAI 2025.
Cardiologists share late-breaking TAVR data on first day of SCAI 2025
New TAVR data on SAPT vs. DAPT and prosthesis-patient mismatch among women were some of the many highlights of the conference's opening day.
Latest EARLY TAVR data suggest it is time to update industry guidelines
Philippe Genereux, MD, principal investigator of EARLY TAVR, presented new data at ACC.25 showing intervening early on crossover patients with asymptomatic severe aortic stenosis led to better outcomes and a reduced stroke rate.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Answering key follow-up questions after the FDA approved TAVR in asymptomatic patients

The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward.

AI predicts LBBB risk in TAVR patients prior to treatment

The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

A super alternative: BATMAN helps cardiologists limit complications during TMVR

The BATMAN technique is a safe, effective way to prevent LVOT obstruction during high-risk transcatheter mitral valve replacement, according to new data presented at SCAI 2025.

Cardiologists share late-breaking TAVR data on first day of SCAI 2025

New TAVR data on SAPT vs. DAPT and prosthesis-patient mismatch among women were some of the many highlights of the conference's opening day.

Philippe Genereux, MD, director of the structural heart program at Morristown Medical Center, principal investigator of the late-breaking EARLY TAVR trial, presented new data at ACC 2025 showing intervening earlier on patients with asymptomatic severe aortic stenosis leads to better outcomes.

Latest EARLY TAVR data suggest it is time to update industry guidelines

Philippe Genereux, MD, principal investigator of EARLY TAVR, presented new data at ACC.25 showing intervening early on crossover patients with asymptomatic severe aortic stenosis led to better outcomes and a reduced stroke rate.

A victory for early treatment: FDA approves first TAVR valves for asymptomatic severe aortic stenosis

The FDA has approved the balloon-expandable Sapien 3 TAVR platform from Edwards Lifesciences for treating asymptomatic severe aortic stenosis. This is the first time the agency has approved any TAVR technology to be used in asymptomatic patients.

Society of Thoracic Surgeons shares new risk calculator for aortic surgeries

Society of Thoracic Surgeons shares new risk calculator for complex aortic procedures

The new resource was built to help care teams plan for ascending aorta and aortic root surgeries.

Robotic mitral valve repair linked to benefits for elderly patients

Robotic and traditional mitral valve repair surgeries are mostly associated with similar outcomes when treating elderly patients. In some ways, however, robotic procedures may be preferred.